Greenland Mines Ltd (NASDAQ: GRML) is moving forward with its transformation into a focused rare earths and critical minerals company, announcing a series of corporate milestones including the planned spin-off of its biotechnology division in the fourth quarter of 2026. The move comes as the company sharpens its focus on the development of its key mining assets in Greenland.
The company revealed that Nasdaq has formally approved its application relating to the March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements. This approval removes a potential overhang and allows the company to proceed with its strategic plans.
In a significant operational step, Greenland Mines completed the acquisition of the Sarfartoq project on Sept. 1, following approval by the Government of Greenland. The Sarfartoq project is a neodymium-praseodymium (NdPr) rare earths project located in southwest Greenland. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%, underscoring the project’s economic potential.
The company stated that the planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China, based on 2025 consumption levels, during each of the project’s nine scheduled operating years. This positions Greenland Mines as a potential significant supplier of these critical magnet metals, which are essential for electric vehicles, wind turbines, and other clean energy technologies.
Greenland Mines is also reshaping its board to align with its new strategic direction. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining the board. These changes are intended to bring fresh expertise as the company advances its Sarfartoq and Skaergaard projects.
The Skaergaard project, located in southeast Greenland, is known for its palladium, gold, and platinum resources. The company’s broader vision includes building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities. This aligns with its ‘North Atlantic Critical Metals Corridor’ vision, which aims to link Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The spin-off of the biotech division, which includes Klotho’s KLTO-202 primary indication for ALS, will allow Greenland Mines to focus entirely on its mining operations. The move is expected to unlock value for shareholders by separating the distinct risk profiles and capital requirements of the two businesses.
Analysts view these developments as a positive step for Greenland Mines, as it addresses previous compliance issues and secures a key asset in the rare earths supply chain. With the global push towards renewable energy and electric vehicles, the demand for NdPr is expected to rise, making the Sarfartoq project strategically important. The company’s ability to deliver on its production targets will be crucial in establishing it as a reliable supplier outside China.
For more information on Greenland Mines, visit the company’s newsroom at https://ibn.fm/GRML.
